Quadria Capital Fund III
Quadria Capital Fund III is a healthcare-focused Asia private-equity vehicle with public India deployment evidence. The manager disclosed the fund's 2025 close and deployment, while company and manager materials identify healthcare platforms including Aragen Life Sciences, NephroPlus, Maxivision Eye Hospitals, Akums and Encube.
At a glance
- Founded
- 2012
- Footprint
- Singapore / Delhi
- Stage
- Healthcare growth equity
Research profile
Read the manager in sequence.
Open a section to inspect the evidence. The first view starts with the investment point of view; the rest stays quiet until you need it.
Investment lens
Quadria Capital Fund III uses a healthcare growth equity approach across Hospitals, pharmaceuticals, diagnostics.
Current evidence
Quadria Capital announced the oversubscribed final close of Fund III at US$1.07 billion in May 2025 and reported early deployment into Aragen Life Sciences, NephroPlus and Maxivision. Its 2025–26 annual review also records the Akums IPO partial exit and continued activity across Fund III healthcare platforms.
Strategy
Healthcare growth equity
Sector focus
Hospitals, pharmaceuticals, diagnostics
Current signal
Quadria Capital announced the oversubscribed final close of Fund III at US$1.07 billion in May 2025 and reported early deployment into Aragen Life Sciences, NephroPlus and Maxivision. Its 2025–26 annual review also records the Akums IPO partial exit and continued activity across Fund III healthcare platforms.
Next step
Need this manager reviewed against your mandate?
Share the allocation question, ticket size, liquidity constraints and existing exposure. Rupeia can determine whether this profile needs a deeper decision-support brief.